$AXSM
Axsome Therapeutics, Inc.

2021 Q1 Form 10-Q Financial Statement

#000156459021026119 Filed on May 10, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $11.25M $4.970M
YoY Change 126.36% 76.24%
% of Gross Profit
Research & Development $16.60M $27.52M
YoY Change -39.7% 262.12%
% of Gross Profit
Depreciation & Amortization $8.326K $5.436K
YoY Change 53.16% -45.64%
% of Gross Profit
Operating Expenses $27.84M $32.49M
YoY Change -14.3% 211.77%
Operating Profit -$27.84M -$32.49M
YoY Change -14.3%
Interest Expense -$1.420M $10.00K
YoY Change -14300.0% -104.55%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$29.26M -$32.48M
YoY Change -9.91% 205.26%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$29.26M -$32.48M
YoY Change -9.93% 205.29%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$781.7K -$876.4K
COMMON SHARES
Basic Shares Outstanding 37.41M
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $164.7M $197.3M
YoY Change -16.52% 363.15%
Cash & Equivalents $164.7M
Short-Term Investments
Other Short-Term Assets $400.0K $300.0K
YoY Change 33.33% -72.73%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $165.0M $197.6M
YoY Change -16.48% 351.14%
LONG-TERM ASSETS
Property, Plant & Equipment $74.32K $0.00
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $317.4K $100.0K
YoY Change 217.38% 0.0%
Total Long-Term Assets $1.868M $200.0K
YoY Change 834.2% 100.0%
TOTAL ASSETS
Total Short-Term Assets $165.0M $197.6M
Total Long-Term Assets $1.868M $200.0K
Total Assets $166.9M $197.8M
YoY Change -15.62% 350.57%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $14.62M $12.20M
YoY Change 19.85% 258.82%
Accrued Expenses $7.100M $9.300M
YoY Change -23.66% 151.35%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $4.600M
YoY Change 820.0%
Total Short-Term Liabilities $21.68M $26.10M
YoY Change -16.92% 238.96%
LONG-TERM LIABILITIES
Long-Term Debt $48.60M $15.50M
YoY Change 213.54% -17.55%
Other Long-Term Liabilities $300.0K
YoY Change
Total Long-Term Liabilities $48.60M $15.50M
YoY Change 213.54% -17.55%
TOTAL LIABILITIES
Total Short-Term Liabilities $21.68M $26.10M
Total Long-Term Liabilities $48.60M $15.50M
Total Liabilities $70.61M $41.60M
YoY Change 69.74% 56.98%
SHAREHOLDERS EQUITY
Retained Earnings -$308.1M
YoY Change
Common Stock $404.3M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $96.29M $156.2M
YoY Change
Total Liabilities & Shareholders Equity $166.9M $197.8M
YoY Change -15.62% 350.57%

Cashflow Statement

Concept 2021 Q1 2020 Q1
OPERATING ACTIVITIES
Net Income -$29.26M -$32.48M
YoY Change -9.93% 205.29%
Depreciation, Depletion And Amortization $8.326K $5.436K
YoY Change 53.16% -45.64%
Cash From Operating Activities -$27.22M -$23.27M
YoY Change 16.94% 144.98%
INVESTING ACTIVITIES
Capital Expenditures $30.00K $9.331K
YoY Change 221.46%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$30.00K -$9.331K
YoY Change 221.46%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $6.116M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 8.029M 629.8K
YoY Change 1174.96% -98.35%
NET CHANGE
Cash From Operating Activities -27.22M -23.27M
Cash From Investing Activities -30.00K -9.331K
Cash From Financing Activities 8.029M 629.8K
Net Change In Cash -19.22M -22.65M
YoY Change -15.17% -179.07%
FREE CASH FLOW
Cash From Operating Activities -$27.22M -$23.27M
Capital Expenditures $30.00K $9.331K
Free Cash Flow -$27.25M -$23.28M
YoY Change 17.02% 145.08%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y6M
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y6M
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y10M24D
CY2021Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
375306
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
148373
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
48321848
CY2021Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
329916
CY2021Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
113792909
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16595689
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11248372
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4970057
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
27844061
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
32491457
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-27844061
CY2021Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
317375
CY2021Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
164660132
CY2020Q4 us-gaap Assets Current
AssetsCurrent
184024826
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
183876453
CY2021Q1 us-gaap Assets Current
AssetsCurrent
165035438
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
317375
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
74316
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
52647
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1476711
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1739475
CY2021Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1196539
CY2021Q1 us-gaap Assets
Assets
166903840
CY2020Q4 us-gaap Assets
Assets
186134323
CY2021Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
14621717
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
13504022
CY2021Q1 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
5864526
CY2020Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
8713249
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1220587
CY2021Q1 us-gaap Liabilities Current
LiabilitiesCurrent
21682782
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
23437858
CY2021Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
48597943
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
581708
CY2021Q1 us-gaap Liabilities
Liabilities
70610641
CY2020Q4 us-gaap Liabilities
Liabilities
72341414
CY2021Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37563882
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37563882
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37374088
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37374088
CY2021Q1 us-gaap Common Stock Value
CommonStockValue
3756
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
3737
CY2021Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
404345506
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
392585265
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-308056063
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-278796093
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
96293199
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
166903840
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
186134323
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
27521400
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3731097
CY2021Q1 axsm Stock Issued During Period Value Financing
StockIssuedDuringPeriodValueFinancing
6115864
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
629756
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-32491457
CY2021Q1 us-gaap Investment Income Net
InvestmentIncomeNet
-1415909
CY2020Q1 us-gaap Investment Income Net
InvestmentIncomeNet
7311
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-29259970
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-32484146
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.78
CY2020Q1 axsm Stock Issued During Period Value Financing
StockIssuedDuringPeriodValueFinancing
7155337
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.88
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37429450
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37061356
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
178722389
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2133530
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-32484146
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
156156866
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
113792909
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1913299
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1117695
CY2020Q1 axsm Increase Decrease In Prepaid Expense And Other Assets Current
IncreaseDecreaseInPrepaidExpenseAndOtherAssetsCurrent
-103725
CY2019Q4 us-gaap Cash
Cash
219966167
CY2020Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
3700
CY2021Q1 us-gaap Cash
Cash
164660132
CY2020Q1 us-gaap Cash
Cash
197313408
CY2021Q1 us-gaap Interest Paid Net
InterestPaidNet
1143750
CY2020Q1 us-gaap Interest Paid Net
InterestPaidNet
379167
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-29259970
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
96293199
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-29259970
CY2020Q1 us-gaap Profit Loss
ProfitLoss
-32484146
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3731097
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2133530
CY2020Q1 axsm Noncash Research And Development Expense
NoncashResearchAndDevelopmentExpense
7155337
CY2021Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
276095
CY2020Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
177652
CY2021Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
262764
CY2021Q1 axsm Change In Operating Lease Liability
ChangeInOperatingLeaseLiability
-275840
CY2021Q1 us-gaap Depreciation
Depreciation
8326
CY2020Q1 us-gaap Depreciation
Depreciation
5436
CY2021Q1 axsm Increase Decrease In Prepaid Expense And Other Assets Current
IncreaseDecreaseInPrepaidExpenseAndOtherAssetsCurrent
226933
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1248389
CY2021Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-2848723
CY2020Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-1609407
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27215489
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23273184
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
29995
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
9331
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-29995
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-9331
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
6115864
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1913299
CY2020Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
629756
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8029163
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
629756
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-19216321
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-22652759
CY2020Q4 us-gaap Cash
Cash
183876453
CY2021Q1 axsm Number Of Late Stage Product Candidates
NumberOfLateStageProductCandidates
5
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-308100000
CY2021Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.92%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management considers many factors in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements if these results differ from historical experience, or other assumptions do not turn out to be substantially accurate, even if such assumptions are reasonable when made. In preparing these financial statements, management used significant estimates in the following areas, among others: stock‑based compensation expense; the determination of the fair value of the warrants; the accounting for research and development costs; and the recoverability of the Company’s net deferred tax assets and related valuation allowance.</p>
CY2021Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
164700000
CY2021Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:6.92%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash. The Company maintains its cash at financial institutions, which at times, exceed federally insured limits. At March 31, 2021, the majority of the Company’s cash was held by one financial institution and the amount on deposit was in excess of Federal Deposit Insurance Corporation insurance limits. The Company has not recognized any losses from credit risks on such accounts since inception. The Company believes it is not exposed to significant credit risk on cash.</p>
CY2021Q1 axsm Number Of Financial Institutions Holding Deposits
NumberOfFinancialInstitutionsHoldingDeposits
1
CY2021Q1 us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P3Y
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
50000000
CY2021Q1 axsm Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
1183367
CY2020Q4 axsm Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
4293522
CY2021Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1165548
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2870261
CY2021Q1 axsm Accrued General And Administrative Current
AccruedGeneralAndAdministrativeCurrent
3121653
CY2020Q4 axsm Accrued General And Administrative Current
AccruedGeneralAndAdministrativeCurrent
1155508
CY2021Q1 us-gaap Interest Payable Current
InterestPayableCurrent
393958
CY2020Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
50000000
CY2021Q1 axsm Debt Instrument Accreted Liability Of Final Payment Fee
DebtInstrumentAccretedLiabilityOfFinalPaymentFee
295493
CY2020Q4 axsm Debt Instrument Accreted Liability Of Final Payment Fee
DebtInstrumentAccretedLiabilityOfFinalPaymentFee
151912
CY2021Q1 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
1697550
CY2020Q4 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
1830064
CY2020Q4 us-gaap Interest Payable Current
InterestPayableCurrent
393958
CY2021Q1 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
5864526
CY2020Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
8713249
CY2021Q1 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
1143750
CY2020Q1 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
379167
CY2021Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
143589
CY2020Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
119014
CY2021Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
48597943
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
48321848
CY2021Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
12193153
CY2021Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
19761468
CY2021Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
18045379
CY2021Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
50000000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-29259970
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-32484146
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37429450
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37061356
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.78
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.88
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4705122
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4181778
CY2021Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
286923
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
950000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
630000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1580000
CY2021Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
53545
CY2021Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
1526455
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
24.94
CY2021Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y3M18D
CY2021Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.060
CY2021Q1 axsm Equity Instrument Voting Rights Per Share
EquityInstrumentVotingRightsPerShare
1
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3725648
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
16.06
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
780440
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
66.72
CY2021Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
94000
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
22.20
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
25844
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
80.72
CY2021Q1 axsm Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod
646
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
87.76
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4385598
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
24.04
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
248407010
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
4379429
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
247912432
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2529258
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
11.03
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
178255864
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
49.26
CY2021Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
54800000
CY2021Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y6M
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
9788
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3731097
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2133530
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
15541
CY2020Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
80.43
CY2021Q1 axsm Warrants Issued In Period
WarrantsIssuedInPeriod
0
CY2021Q1 axsm Warrants Issued In Period Weighted Average Exercise Price
WarrantsIssuedInPeriodWeightedAverageExercisePrice
0
CY2021Q1 axsm Warrants Exercised In Period
WarrantsExercisedInPeriod
0
CY2021Q1 axsm Warrants Exercised In Period Weighted Average Exercise Price
WarrantsExercisedInPeriodWeightedAverageExercisePrice
0
CY2021Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
15541
CY2021Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
80.43

Files In Submission

Name View Source Status
0001564590-21-026119-index-headers.html Edgar Link pending
0001564590-21-026119-index.html Edgar Link pending
0001564590-21-026119.txt Edgar Link pending
0001564590-21-026119-xbrl.zip Edgar Link pending
axsm-10q_20210331.htm Edgar Link pending
axsm-10q_20210331_htm.xml Edgar Link completed
axsm-20210331.xsd Edgar Link pending
axsm-20210331_cal.xml Edgar Link unprocessable
axsm-20210331_def.xml Edgar Link unprocessable
axsm-20210331_lab.xml Edgar Link unprocessable
axsm-20210331_pre.xml Edgar Link unprocessable
axsm-ex311_9.htm Edgar Link pending
axsm-ex312_8.htm Edgar Link pending
axsm-ex321_7.htm Edgar Link pending
axsm-ex322_6.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending